公开资料显示，微创医疗科学有限公司起源于1998年5月在上海张江高科技园区成立的微创医疗器械（上海）有限公司，为中国领先的高端医疗器械集团。目前“微创系”共有6家上市公司，分别是母公司微创医疗，以及心脉医疗、心通医疗、微创机器人、微创脑科学、微电生理5家子公司。据悉，公司2021年6月发行的7亿美元可转债于2024年6月可被投资人要求赎回，公司自2023年底起采取多种途径筹资，包括发行新可转债、可换股定期贷款融资、获取金融机构信贷支持等方式，短期流动性风险已得到化解。The entire MEDPORT group is rising, as of the report, MEDBOT-B (02252) is up 26.05%, reported at 11.66 HKD; MICROPORT (00853) is up 11.6%, reported at 6.83 HKD; Siasun Robot&Automation (02172) is up 9.14%, reported at 9.79 HKD; CARDIOFLOW-B (02160) is up 2.86%, reported at 0.72 HKD.
According to the Zhitong Finance APP, the entire MEDPORT group is rising, as of the report, MEDBOT-B (02252) is up 26.05%, reported at 11.66 HKD; MICROPORT (00853) is up 11.6%, reported at 6.83 HKD; Siasun Robot&Automation (02172) is up 9.14%, reported at 9.79 HKD; CARDIOFLOW-B (02160) is up 2.86%, reported at 0.72 HKD.
In terms of news, Shanghai has issued the "Action Plan for Supporting Listed Companies to Carry Out Mergers and Acquisitions (2025-2027)." The plan proposes to introduce professional market-oriented merger fund managers and attract the gathering of market-oriented merger funds, with qualified entities included in a fast track for Private Equity fund establishment. Make good use of the 10 billion yuan integrated circuit design industry merger fund and establish a 10 billion yuan Biomedical industry merger fund. In addition, in July, Shanghai issued "Several Opinions on Supporting the Whole Chain Innovation and Development of the Biomedical Industry," proposing the establishment of a Shanghai Biomedical Industry merger fund, actively guiding qualified Biomedical enterprises to initiate the establishment of merger funds based on industry transformation and upgrading needs, and supporting enterprises in conducting merger investments along the Industry Chain.
Public information shows that MICROPORT Scientific Company Limited originated from the establishment of MEDICAL INSTRUMENTS (Shanghai) Co., Ltd. in May 1998 at the Shanghai Zhangjiang Hi-Tech Park Development, becoming a leading high-end medical instruments group in China. Currently, the "MEDPORT group" has a total of 6 listed companies, including the parent company MICROPORT, and its five subsidiaries: Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd., CARDIOFLOW, Siasun Robot&Automation, MEDBOT, and Siasun Robot&Automation. It is reported that the company issued 0.7 billion USD Convertible Bonds in June 2021, which can be redeemed by investors in June 2024. The company has taken various approaches to raise funds since the end of 2023, including issuing new Convertible Bonds, issuing convertible loan financing, and obtaining support from Financial Institutions, successfully resolving short-term liquidity risks.
